Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients.
about
The Regulatory Roles of MicroRNAs in Bone Remodeling and Perspectives as Biomarkers in OsteoporosisHepatic Stellate Cells and microRNAs in Pathogenesis of Liver FibrosisHost-Targeting Agents to Prevent and Cure Hepatitis C Virus InfectionChronic hepatitis C virus infection and lipoprotein metabolismThe MYC/miR-17-92 axis in lymphoproliferative disorders: A common pathway with therapeutic potentialMouse Systems to Model Hepatitis C Virus Treatment and Associated ResistanceMicroRNAs in Coronary Heart Disease: Ready to Enter the Clinical Arena?Regulatory non-coding RNAs in acute myocardial infarctionAn Interferon Regulated MicroRNA Provides Broad Cell-Intrinsic Antiviral Immunity through Multihit Host-Directed Targeting of the Sterol PathwayRNase P Ribozymes Inhibit the Replication of Human Cytomegalovirus by Targeting Essential Viral Capsid ProteinsRNA Interference-Guided Targeting of Hepatitis C Virus Replication with Antisense Locked Nucleic Acid-Based Oligonucleotides Containing 8-oxo-dG Modifications.IL-4 Induced Innate CD8+ T Cells Control Persistent Viral Infection.In vitro and in vivo activity of miR-92a-Locked Nucleic Acid (LNA)-Inhibitor against endometrial cancer.Antisense-mediated reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial.Novel insights into a reputably irreversible process: combined mRNA and miRNA profiling of tissue from vesicourethral anastomotic stenosis after radical prostatectomy.The Role of MicroRNAs in Antiarrhythmic Therapy for Atrial Fibrillation.TALEN/CRISPR-mediated engineering of a promoterless anti-viral RNAi hairpin into an endogenous miRNA locus.Locked nucleic acid-inhibitor of miR-205 decreases endometrial cancer cells proliferation in vitro and in vivo.MicroRNAs as therapeutic targets in atherosclerosis.Thinking small: towards microRNA-based therapeutics for anxiety disorders.Non-Coding RNAs in Primary Liver Cancer.Dual therapy of grazoprevir and elbasvir for the treatment of hepatitis C infection.Why highly effective drugs are not enough: the need for an affordable solution to eliminating HCV.MicroRNAs in metabolism.MicroRNAs 33, 122, and 208: a potential novel targets in the treatment of obesity, diabetes, and heart-related diseases.The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market.Updates and current challenges in microRNA research for personalized medicine in ovarian cancer.Improved microRNA suppression by WPRE-linked tough decoy microRNA sponges.Short (16-mer) locked nucleic acid splice-switching oligonucleotides restore dystrophin production in Duchenne Muscular Dystrophy myotubes.Miravirsen dosing in chronic hepatitis C patients results in decreased microRNA-122 levels without affecting other microRNAs in plasma.MicroRNA-351 inhibits denervation-induced muscle atrophy by targeting TRAF6The Clinical Application of MicroRNAs in Infectious DiseaseTherapeutic targeting of non-coding RNAs in cancer.Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease.Epigenetics: The Future Direction in Systemic Sclerosis.Inhibition of microRNA-210 suppresses pro-inflammatory response and reduces acute brain injury of ischemic stroke in mice.Development of Novel Therapeutic Agents by Inhibition of Oncogenic MicroRNAs.Covalent Strategies for Targeting Messenger and Non-Coding RNAs: An Updated Review on siRNA, miRNA and antimiR Conjugates.Anti-miRNA oligonucleotides: A comprehensive guide for design.Putting a brake on stress signaling: miR-625-3p as a biomarker for choice of therapy in colorectal cancer.
P2860
Q26748699-2163E7A8-FD12-416F-85D0-8D7475B9B9E6Q26752932-A8C5BC1B-E2C0-46B1-906F-430F0926B19AQ26779128-ED7C1DB1-2517-415F-AFA1-73BF8B6B329DQ26784234-C36FA7D4-9A17-4535-A18D-8E1939BC7AAEQ26797469-6B0A01D6-9A30-4297-A077-BAF510EC7034Q27469038-19C10C13-DE86-4273-8071-919E8A63E780Q28076541-C23AF9A7-0C12-4D28-9B42-A8115BA9CC51Q28077279-ADFFDF78-BE68-4926-9570-542CB4B29E5CQ28550521-A1DF6DE8-383D-4A45-A116-568DCCE49BD5Q28646176-59AF98A5-C298-41FC-867E-ADD68B69599DQ35650955-6D37E8DF-087F-49F2-99AC-653BEA0451D7Q35801754-3CBF70F5-B69E-48A7-A66B-768D36567B46Q36174701-F4BED72F-2364-4EDB-80AC-A899C8B52881Q36410111-E09D7CA0-FB8A-4E3E-893D-1CFE7C0B26FAQ36410973-CE73DF4E-116C-4956-A848-94F685DE8637Q36518163-65EB8F84-AB0C-455F-BF93-DE91D1C2BFCCQ37577414-2229C772-8F98-49D4-93D1-589B0DEF8312Q37687451-45750190-3B82-42B0-B82E-9370F10AB7B6Q38281268-D82C16C6-CAAA-43FE-A963-F4068E626F54Q38310488-03BBA99F-1BE7-4E15-B67C-B432BE21B189Q38541359-21BFFBD5-5C2A-473C-AE2F-0DD475246F16Q38714156-7AF40992-A6B6-4104-B070-0F918D941266Q38735359-F3398B70-FCBA-491E-B0C0-7BAC517A1C60Q38786731-7F1957DE-872B-4E18-B648-18DD1C3E9CCFQ39038069-51CA4008-0AB2-491F-9C9F-EAF113BCFD88Q39227810-7738ABBA-5917-403C-801E-2DE2F5C4CAE1Q39391417-246CFF70-FAB0-49C1-BB03-38A0E87B44C4Q40208488-E0E72CD8-DADD-4494-899B-017971122120Q41106058-C48BBEC1-1FC5-4AEA-8000-355D6F64242FQ41183377-7BC12F5C-D5DF-49FC-A1F7-53E1051B1015Q41398425-E71ECDE8-7D48-4891-AB85-03DA952B3D49Q41921194-EECAAA96-2B6E-4A95-9FB2-B0342C3444A6Q47292099-97A17B4A-C18D-4C0E-BD11-8ED704C3173BQ47913152-A02A261B-DDFE-47DB-95F7-5245CF5F2C6AQ47939031-0249BC97-0FDD-44AB-8387-AEA3AE52E313Q47982210-D4717407-7882-4633-8F0D-0B353B1FA296Q48343656-DDB005C7-FA02-46E4-A150-905742E35861Q50131778-2600A239-D755-4505-82C4-C758EACFBE42Q52640764-D30D4036-9A7E-4838-A154-C7988311556AQ53762655-88C4A76D-7497-4DB9-9C9B-25BDA1F22F49
P2860
Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Long-term safety and efficacy ...... chronic hepatitis C patients.
@ast
Long-term safety and efficacy ...... chronic hepatitis C patients.
@en
Long-term safety and efficacy ...... chronic hepatitis C patients.
@nl
type
label
Long-term safety and efficacy ...... chronic hepatitis C patients.
@ast
Long-term safety and efficacy ...... chronic hepatitis C patients.
@en
Long-term safety and efficacy ...... chronic hepatitis C patients.
@nl
prefLabel
Long-term safety and efficacy ...... chronic hepatitis C patients.
@ast
Long-term safety and efficacy ...... chronic hepatitis C patients.
@en
Long-term safety and efficacy ...... chronic hepatitis C patients.
@nl
P2093
P1433
P1476
Long-term safety and efficacy ...... chronic hepatitis C patients.
@en
P2093
Adriaan J van der Meer
Alcija Wiercinska-Drapalo
Andre van Vliet
Eric J Lawitz
Harry L A Janssen
Hendrik W Reesink
Joep de Bruijne
Maribel Rodriguez-Torres
Meike H van der Ree
Michael R Hodges
P356
10.1016/J.ANTIVIRAL.2014.08.015
P577
2014-09-08T00:00:00Z